Skip to main content
. 2022 Nov 14;10(1):e200052. doi: 10.1212/NXI.0000000000200052

Figure 2. Kaplan-Meier Estimates for Time to 6mCDP.

Figure 2

The risk of 6mCDP is compared in patients with (A) sNfL and (B) sGFAP above vs below the median. The risk of 6mCDP is then investigated in only patients with (C) sGFAP below the median or (D) sNfL below the median. For example, D considers only the 129 patients who have a level of sNfL below the median of the cohort; in this group, the risk for 6mCDP is compared between the 81 patients who have a sGFAP level above the median of the cohort and the 48 patients who have a sGFAP level below the median of the cohort. 6mCDP = 6-month confirmed disability progression; GFAP = glial fibrillary acidic protein; NfL = neurofilament light chain; sGFAP = serum GFAP; sNfL = serum NfL.